| Cash Flow | 2025-06-30 |
|---|---|
| Net loss | -9,466,966 |
| Preferred shares issued as compensation | 60,722 |
| Common shares issued as compensation and for services | 162,625 |
| Warrants granted to scientific advisory board | 679 |
| Depreciation | 735,536 |
| Amortization | 8,269 |
| Prepaid expenses | 60,596 |
| Other assets | 12,117 |
| Accounts payable | 82,824 |
| Accounts payable - related parties | 101,417 |
| Accrued expenses | -236,498 |
| Net cash used in operating activities | -8,478,679 |
| Purchase of property and equipment | -56,964 |
| Net cash used in investing activities | -56,964 |
| Net proceeds from sale of common stock | 5,296,429 |
| Net cash provided by financing activities | 5,296,429 |
| Net change in cash and cash equivalents | -3,239,214 |
| Cash and cash equivalents at beginning of period | 4,797,778 |
| Cash and cash equivalents at end of period | 1,558,564 |
NANOVIRICIDES, INC. (NNVC)
NANOVIRICIDES, INC. (NNVC)